Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares 3 7 Year Treasury Bond ETF (IEI) vs Viatris Inc (VTRS) Price & Performance

iShares 3 7 Year Treasury Bond ETFTrade
Viatris IncTrade

Price performance (Past 24H)

Key statistics

iShares 3 7 Year Treasury Bond ETF vs Viatris Inc — how do they compare? iShares 3 7 Year Treasury Bond ETF trades at $113.49 (market cap $16.72B), while Viatris Inc trades at $17.64 (market cap $20.03B). The key difference: Viatris Inc is the larger of the two by market cap, and Viatris Inc pays a 2.75% dividend while iShares 3 7 Year Treasury Bond ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares 3 7 Year Treasury Bond ETF for 43 Days and Viatris Inc for 57 Days on average.

IEIVTRS
Market Cap
$16.72B$20.03B
Volume
3,963,31914,109,977
Sector
Fixed IncomeHealth
52-Week High
$120.72$18.27
52-Week Low
$113.17$9.74
Typical Hold Time
43 Days57 Days
Enterprise Value
—$32.15B
Dividend Yield
—2.75%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares 3 7 Year Treasury Bond ETF

IEI trades at $113.57 with minimal daily movement (+0.17%), showing stability amid broader market volatility. The technical picture remains bearish with moving averages signaling downward pressure, though oscillators suggest neutral momentum. Recent dividend payments of $0.37-0.38 per share demonstrate consistent shareholder returns. The stock faces headwinds from rising Treasury yields and bond market volatility, which could impact investor appetite for equities.

Outlook remains cautious as higher interest rates and bond market turbulence create challenging conditions. The bearish technical signals and neutral fundamental metrics suggest limited near-term upside potential. Key risks include continued bond market volatility and macroeconomic pressures, though consistent dividend payments provide some defensive characteristics for income-focused investors.

Viatris Inc

Viatris (VTRS) trades at $17.44, down 0.29% on the day, with a bullish technical signal from moving averages and oversold short-term RSI. The company reported three consecutive quarterly earnings beats in 2026, with Q2 EPS of $0.69 beating estimates by 14.8%. Revenue for 2025 was $14.3B, though net income was negative $3.51B, reflecting margin pressure. Positive news includes a new drug approval in Japan and recognition as a top employer.

The outlook is mixed: strong cash flow generation and deleveraging support shareholder returns via dividends and buybacks, but profitability challenges and high debt levels pose risks. Analyst consensus is a 'Buy' with a $22.17 price target, implying 27% upside. Investment appeal hinges on execution of pipeline growth and margin improvement amid competitive and pricing pressures in the generics market.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

IEI

No sentiment data available yet.

VTRS
100% Buy0% Sell
Avg holding period · 57 Days

Top news

Latest headlines on both assets

About iShares 3 7 Year Treasury Bond ETF

IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.

Read more on IEI →

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS →